



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/308,223
Applicant : Georg KALLMEYER et al
Filed : August 12, 1999
TC/A.U. : 1642
Examiner : Brandon J. Fetterolf

Docket No. : 2924-139
Customer No. : 06449
Confirmation No. : 5876

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449. The references were cited in a European Opposition filed in the European application.


In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

By 
Monica Chin Kitts
Attorney for Applicant
Registration No. 36,105
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

MCK/cb



 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>				<i>Complete if Known</i>	
				Application Number	09/308,223
				Filing Date	August 12, 1999
				First Named Inventor	Georg Kallmeyer
				Group Art Unit	1642
				Examiner Name	Brandon J. Fetterolf
				Confirmation No.	5876
Sheet	1	of	3	Attorney Docket Number	2924-139

U.S. PATENT DOCUMENTS

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	09/308,223
Filing Date	August 12, 1999
First Named Inventor	Georg Kallmeyer
Group Art Unit	1642
Examiner Name	Brandon J. Fetterolf
Confirmation No.	5876

Sheet	2	of	3	Attorney Docket Number	2924-139
-------	---	----	---	------------------------	----------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
		EP	0 733 702	A1	Behringwerke Aktiengesellschaft	9/25/96	
		WO	94/14465	A1	Boehringer Mannheim GmbH	7/7/94	
		WO	94/07510	A1	Kabi Pharmacia AB	4/14/94	
		WO	95/07108	A2	Genetics Institute Inc.	3/16/95	
		EP	0 689 843	A1	Mochida Pharmaceutical Co.	1/3/96	
		CZ	247484	B1	Hanšíková, et al	5/15/86	x
		WO	97/04801	A1	Genentech Inc.	2/13/97	
		EP	0 196 761	A2	The Green Cross Corporation	10/8/86	
		WO	92/01442	A1	Farmitalia Carlo Erba S.r.L.	2/6/92	
		WO	89/09614	A1	Genentech Inc.	10/19/89	
		EP	96118489.2		Boehringer Mannheim GmbH	1/29/98	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

				Complete if Known	
				Application Number	09/308,223
				Filing Date	August 12, 1999
				First Named Inventor	Georg Kallmeyer
				Group Art Unit	1642
				Examiner Name	Brandon J. Fetterolf
				Confirmation No.	5876
Sheet	3	of	3	Attorney Docket Number	2924-139

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Manning et al., "Stability of Protein Pharmaceuticals", PHARMACEUTICAL RESEARCH, vol. 6, no. 11, 1989, pgs. 903-918.	
		Hanson et al., "Introduction of Formulation of Protein Pharmaceuticals", Chapter 7 in Stability of Protein Pharmaceuticals, Part B in Vivo Pathways of Degradation and Strategies for Protein Stabilization, 1992.	
		Nema et al., "Freeze-Thaw Studies of A Model Protein, Lactate Dehydrogenase, in the Presence of Cryoprotectants", J PARENT.SCI. TECHNOL., 47, S. 76-83 (1993).	
		Rote Liste 1996, published 11/95	
		Inventory of Ingredients used in cosmetic products, : SO, 9/8/03	
		Bioplasma FDP lyophilised powder for IV infusion. Package insert, 1/2002.	
		Opposition in European Patent No. 0941121B, June 20, 2005.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.